International Clinical Trial: The efficacy and safety of Huairu Granules combined with chemotherapy and immunotherapy as first-line treatment for extensive-stage small cell lung cancer: A single-arm, prospective, phase II study

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114626) titled 'The efficacy and safety of Huairu Granules combined with chemotherapy and immunotherapy as first-line treatment for extensive-stage small cell lung cancer: A single-arm, prospective, phase II study' on Dec. 16, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Huzhou Central Hospital

Condition: Small cell lung cancer

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2025-12-23

Target Sample Size: Huai 'er Granules Combined Treatment Group:60;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=298342

Pu...